Genmab disclosed that worldwide net trade sales of DARZALEX, the multiple‑myeloma antibody developed with Johnson & Johnson, reached $3.964 billion in the first quarter of 2026. U.S. sales accounted for $2.208 billion, while sales outside the United States totaled $1.756 billion, underscoring the drug’s global reach.
The figure represents the most recent revenue snapshot for Genmab’s flagship product, which generates the majority of the company’s royalty income—roughly two‑thirds of total revenue. In 2017, DARZALEX net sales were $1.242 billion, with $884 million in the U.S. and $358 million internationally, illustrating a long‑term growth trajectory that has continued into 2026.
Genmab’s management highlighted that DARZALEX royalties will begin to decline materially after 2029 as patents expire, reinforcing the urgency of the company’s transition strategy. The firm is guiding for approximately 14% revenue growth in 2026, driven by its proprietary pipeline, including late‑stage assets such as EPKINLY, Rina‑S, and petosemtamab, which are expected to launch in 2027 and could generate peak sales of $2–3 billion each.
Investors reacted positively to the robust sales, but remained cautious about the impending patent cliff. The strong Q1 performance provides short‑term cash flow, yet the long‑term outlook hinges on the successful commercialization of Genmab’s own therapies to replace the DARZALEX royalty stream.
The DARZALEX sales data also serve as a benchmark for Genmab’s royalty income, which is a critical component of its financial health. The company’s ability to sustain high sales levels while expanding its own product portfolio will determine whether it can maintain profitability once the DARZALEX patent protection ends.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.